Home
Resources
Publications
FGF-23 and Cardiovascular Disease: Review of Literature

FGF-23 and Cardiovascular Disease: Review of Literature

Jasveen Batra, Rupinder Singh Buttar, Pardeep Kaur, Jacqueline Kreimerman, Michal L Melamed

Curr Opin Endocrinol Diabetes Obes. 2016 Dec;23(6):423-429.

PMID: 27652999

Abstract:

Purpose of review:
This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease.
Recent findings:
FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality.
Conclusion:
Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42413253	FGF-23 human			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: